Clinical Trials

Inclusion Criteria:

• Male or female outpatients with confirmed MCI diagnosis or who are cognitively unimpaired (CU) as verified by the Montreal Cognitive Assessment (MoCA) scoring ≥26.
• Age 55-85.
• Right handed (tested using the Edinburgh handedness inventory [19]).
• Total PHQ-8 of ≤ 9 which signifies no moderate or severe depression [20].
• All participants and/or caregivers must be able to provide informed consent.

Exclusion Criteria:

• Neurodegenerative disease (e.g. Parkinson's, Huntington's, Multiple Sclerosis) other than MCI.
• Previous brain lesion.
• Intracranial abnormality such as prior stroke.
• History of seizure disorder or epilepsy.
• A "true" positive response, after patient clarification, to any question on the modified TMS/tDCS Adult Safety Screen questionnaire that would impact patient safety.
• Any history of brain stimulation treatment (e.g., electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagal nerve therapy (VNS), deep brain stimulation (DBS)).
• Use of any investigational drug within 4 weeks.
• Cardiac pacemakers, implanted medication pumps, intracardiac lines; acute or unstable cardiac disease; intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (exception: mouth/dental work) that cannot be safely removed.
• Known or suspected pregnancy (extremely unlikely as the age range for this study is 55-85 years).